Merrimack Pharmaceuticals (MACK) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Merrimack Pharmaceuticals | 10-Q: Q1 2024 Earnings Report
SECMay 15 22:44 ET · Announcements
Vicore Expands and Strengthens Its Board of Directors
AccesswireMay 14 02:20 ET
Merrimack Pharmaceuticals Shareholders OK Dissolution Plan
WSJMay 10 16:47 ET
Express News | Merrimack Pharmaceuticals Inc: Merrimack's Common Stock Will Trade on Nasdaq Through May 17, 2024 and Will Delist From Nasdaq on May 20, 2024
ReutersMay 10 16:30 ET
Express News | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock
ReutersMay 10 16:30 ET
Express News | Merrimack Set for $15.10 per Share Liquidating Dividend
ReutersMay 9 07:31 ET

Comments

Trytosaveabit

Mar 27 16:36

News

$Elevation Oncology (ELEV.US)$ $Merrimack Pharmaceuticals (MACK.US)$ Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...

2

Meltyy

Feb 20 21:07

PDUFA Update…

4 FDA approvals last week
1 PDUFA event left in Feb 2024
Last week’s PDUFAs:
$AstraZeneca (AZN.US)$ : Approved 2/16
⇒ Tagrisso (osimertinib) + chemotherapy
⇒ NSCLC
⇒ sNDA
⇒ PDUFA: Q1 2024
$Iovance Biotherapeutics (IOVA.US)$ : Approved 2/16
⇒ AMTAGVI™ (lifileucel)
⇒ Melanoma
⇒ BLA
⇒ PDUFA: 02/24/24
$ROCHE HOLDING AG (RHHBY.US)$ : Approved 2/16
⇒ Xolair® (omalizumab)
⇒ IgE-mediated food allergy
⇒ sBLA
⇒ PDUFA: Q1 2024
$IPSEY & $Merrimack Pharmaceuticals (MACK.US)$ : Approved 2/13
⇒ ...

8

1

Meltyy

Jan 30 03:28

PDUFA Update…

📌Last week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia (LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies (THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...

12

1

Moomoo AI

Nov 2, 2023 22:42

Chairman Gary Crocker highlighted that interest income on cash and short term investments helped offset a significant portion of Q3 operating expenses. He also noted the company keeps observing developments in Ipsen's Onivyde(R) and Elevation's seribantumab programs.

Press Release: Merrimack Reports Third Quarter 2023 Financial Results

BioPharm Insight US

Nov 14, 2022 10:07

Columns Weekly FDA Drug Pipeline Calendar (Nov 14 - Nov 19)

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
$Moderna (MRNA.US)$'s new Covid booster triggered a stronger immune response against omicron BA.5 and also appears to work against the emerging BQ.1.1 subvariant, according to the company.
The U.S. Covid public health emergency will remain in place past Jan. 11 after the federal government did no...

8

2

MACK Merrimack Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target